GOT2 and neoplasm: The tumour-to-blood (T/B) activity concentration ratio of GOT2-bearing mice is about 50 [30], while some MTC patients have a much higher expression of SSTRs and consequently higher T/B values (up to 350 for 111In-octreotide) and can therefore benefit from PRRT [12, 31].